TREAT PTSD TRICARE Act

The TREAT PTSD TRICARE Act authorizes the provision of stellate ganglion block therapy for active duty and reserve military members diagnosed with post-traumatic stress disorder who are enrolled in the TRICARE program. Under this legislation, eligible service members must receive informed consent regarding the risks and benefits of the procedure before it can be administered by a Department of Defense facility or a participating TRICARE provider. Additionally, the bill requires the Secretary of Defense to update the VA/DoD clinical practice guideline within 180 days to include this new therapy option and its clinical indicators. These changes take effect 180 days after the bill is enacted, ensuring the treatment is integrated into official medical guidelines alongside its implementation.